Moderna (MRNA) PT Raised to $179 at Oppenheimer, 'mResvia is competitive as an RSV vaccine'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval
June 12, 2024 7:45 AM EDTOppenheimer upped their price target on Moderna (NASDAQ: MRNA) after the US drugmaker recently saw its respiratory syncytial virus (RSV) vaccine, known as mRESVIA, approved by the Food and Drug Administration (FDA).
According to Oppenheimer, mResvia is entering the adult market (ages 60 and above), where it will... More
